There have been significant decreases in malaria mortality and morbidity in the last 10-15
years, and the most advanced pre-erythrocytic malaria vaccine, RTS, S, received a positive …

The demonstration of efficacy of two candidate malaria vaccines in children living in malaria-
endemic areas, namely RTS, S from the circumsporozoite protein that reduced infection and …

Abstract Background RTS, S/AS01 is the first malaria vaccine to be approved and
recommended for widespread implementation by the World Health Organization (WHO) …

A malaria vaccine as part of the integrated malaria control and elimination efforts will have a
major impact on public health in sub-Sahara Africa. The first malaria vaccine, RTS, S, now …

Malaria is still killing over one million people each year and its incidence is increasing. The
need for an effective vaccine is greater than ever. A major difficulty with vaccine research is …

Background: The WHO recommended the use of the RTS, S/AS01 malaria vaccine (RTS, S)
based on a pilot evaluation in routine use in Ghana, Kenya, and Malawi. A longitudinal …

Abstract Background RTS, S/AS01 is the first vaccine against malaria to undergo pilot
implementation, beginning in 2019 and vaccinating 360,000 children per year in Malawi …

Introduction: The challenge to eradicate malaria is an enormous task that will not be
achieved by current control measures, thus an efficacious and long-lasting malaria vaccine …

In October, 2021, WHO recommended that the RTS, S malaria vaccine, with its strong safety
profile and high impact, be provided to children from age 5 months in regions with moderate …

Background Studies conducted thus far have demonstrated that the malaria vaccine (RTS,
S) has a promising safety profile. Within the context of planning for future vaccine trials and …